Status:
COMPLETED
Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Gastrointestinal Bleeding
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This double-blind, randomized trial aims to evaluate whether uninterrupted anti-platelet therapy (clopidogrel) will increase the risk of bleeding associated with removal of polyp during colonoscopy in...
Detailed Description
Clopidogrel is a potent anti-platelet agent that, when combines with aspirin, is essential in treating acute myocardial infarction and preventing coronary stent thrombosis. However, adding clopidogrel...
Eligibility Criteria
Inclusion
- On regular treatment with clopidogrel alone or in combination with other anti-platelet drugs (e.g. aspirin)
- Elective colonoscopy for asymptomatic screening of bowel cancer or investigation of bowel symptoms (e.g. altered bowel habit, rectal bleeding, anemia, polyp follow-up)
- Age ≥ 18
- Written informed consent
Exclusion
- Coronary stent of any type placed within 30 days
- Cardiac-vascular event within 3 months
- Drug-eluting coronary stent placed within 6 months
- Terminal illness
- Concomitant use of anticoagulants
- Congenital or acquired bleeding diathesis showing clinical bleeding tendency (e.g. hemophilia, decompensated cirrhosis)
- Pregnancy or women of child-bearing age without regular use of contraception
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2018
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT01806090
Start Date
February 1 2012
End Date
April 1 2018
Last Update
January 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Hong Kong, Hong Kong, China